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ransforming growth factor-
 
 
 
s (TGF-
 
 
 
) are secreted as
inactive complexes containing the TGF-
 
 
 
, the TGF-
 
 
 
propeptide, also called the latency-associated protein
(LAP), and the latent TGF-
 
 
 
 binding protein (LTBP). Extracel-
lular activation of this complex is a critical but incompletely
understood step in TGF-
 
 
 
 regulation. We have investigated
the role of LTBP in modulating TGF-
 
 
 
 generation by the
integrin 
 
 
 
V
 
 
 
6
 
. We show that even though 
 
 
 
v
 
 
 
6
 
 recognizes
an RGD on LAP, LTBP-1 is required for 
 
 
 
V
 
 
 
6
 
-mediated latent
TGF-
 
 
 
 activation. The domains of LTBP-1 necessary for
T
 
activation include the TGF-
 
 
 
 propeptide-binding domain
and a basic amino acid sequence (hinge domain) with
ECM targeting properties. Our results demonstrate an
LTBP-1 isoform-speciﬁc function in 
 
 
 
V
 
 
 
6
 
-mediated latent
TGF-
 
 
 
 activation; LTBP-3 is unable to substitute for LTBP-1
in this assay. The results reveal a functional role for LTBP-1
in latent TGF-
 
 
 
 activation and suggest that activation of
speciﬁc latent complexes is regulated by distinct mechanisms
that may be determined by the LTBP isoform and its potential
interaction with the matrix.
 
Introduction
 
A growth factor that is released into the extracellular space
must reach the appropriate target cell in biologically relevant
concentrations at the correct time despite the random nature
of diffusion. To augment the basic process of diffusion,
multicellular organisms use the ECM to bind, concentrate,
store and present growth factors. A common strategy used
by numerous growth factors, including FGF and VEGF,
to oppose entropy is to rely on charge-based association
with ECM glycosaminoglycans and/or proteins (Flaumen-
haft and Rifkin, 1992b; Taipale and Keski-Oja, 1997). The
cytokine TGF-
 
 
 
 exploits an interesting variation on this
theme of ECM binding. TGF-
 
 
 
 is secreted constitutively in
covalent association with an ECM component, the latent
TGF-
 
 
 
 binding protein (LTBP). In addition, TGF-
 
 
 
 is
secreted in a latent state and must undergo a highly regu-
lated activation process to be functional. An important and
unresolved issue in TGF-
 
 
 
 biology regards the connection
between matrix incorporation and activation of the latent
TGF-
 
 
 
 complex.
The TGF-
 
 
 
s are multipotent cytokines that modulate cell
growth, inflammation, matrix synthesis, and apoptosis (Taipale
et al., 1998). Defects in TGF-
 
 
 
 function are associated with
a number of pathological states including tumor cell growth,
fibrosis, emphysema, and autoimmune disease (Blobe et al.,
2000; Morris et al., 2003). All three mammalian TGF-
 
 
 
isoforms: TGF-
 
 
 
1, 2, and 3 are synthesized as homodimeric
proproteins (proTGF-
 
 
 
). The dimeric propeptides, also
known as the latency-associated protein (LAP), are cleaved
from the mature TGF-
 
 
 
 dimer by furin-type enzymes but
remain noncovalently associated with the mature cytokine
(Dubois et al., 1995). The association between the TGF-
 
 
 
1,
2, and 3 prodomains (LAPs) and the corresponding mature
growth factors prevents signaling through the TGF-
 
 
 
 high
affinity receptors (Lawrence et al., 1984). Thus, TGF-
 
 
 
bioactivity requires dissociation from LAP, a process termed
latent TGF-
 
 
 
 activation.
Early in the assembly of the TGF-
 
 
 
 latent complex, disulfide
linkages are formed between cysteine(s) of LAP and specific
cysteines in the LTBP (Miyazono et al., 1991; Gleizes et al.,
1996; Saharinen et al., 1996). The ternary complex of
TGF-
 
 
 
, LAP, and LTBP is called the large latent complex
(LLC; Fig. 1 A). Under most conditions, TGF-
 
 
 
 is secreted
as part of the LLC (Taipale et al., 1998), which is consistent
with the observation that LTBP-1 and TGF-
 
 
 
1 expression
are coregulated (Miyazono et al., 1991; Koski et al., 1999).
The release of LAP–TGF-
 
 
 
, the small latent complex (SLC),
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without LTBP has been reported previously (Dallas et al.,
1994), but this complex is inefficiently secreted (Miyazono et
al., 1991). The biologic significance of these two different
forms, LLC and SLC, of latent TGF-
 
 
 
 is unclear.
LTBP-1 is a member of the LTBP/fibrillin protein family
comprised of fibrillin-1, -2, and -3, and LTBP-1, -2, -3, and
-4 (Ramirez and Pereira, 1999). These proteins contain multi-
ple EGF-like repeats as well as unique domains containing
eight cysteines or cysteine rich (CR) domain (Kanzaki et al.,
1990; Tsuji et al., 1990; Sinha et al., 1998). LTBP-1, -3, and
-4 form a subset within the family based on their ability to
bind LAP. Only the third of the four CR domains within each
of the LAP-binding LTBPs can disulfide bond to LAP (Sahar-
inen and Keski-Oja, 2000; Lack et al., 2003). LTBP and its
bound latent TGF-
 
 
 
 are found primarily as components of
the ECM (Taipale et al., 1994b). Previous work has impli-
cated the NH
 
2
 
-terminal region of LTBP-1 in ECM binding
(Nunes et al., 1997; Dallas et al., 2000; Unsold et al., 2001),
and the NH
 
2
 
-terminal region of LTBP-1 may be cross-linked
to ECM proteins by tissue transglutaminase (tTGase; Nunes
et al., 1997). At present, the function of the various LTBP iso-
forms and their splice variants remains indeterminate.
The integrin 
 
 
 
v
 
 
 
6
 
 is an in vivo activator of latent TGF-
 
 
 
1
and 3 (Munger et al., 1999; Annes et al., 2002). The expres-
sion of 
 
 
 
v
 
 
 
6
 
 is restricted to epithelia, and in most epithelia the
integrin is normally expressed at low levels (Breuss et al.,
1993). Mice lacking the 
 
 
 
6
 
 subunit have persistent lung and
skin inflammation but do not develop pulmonary fibrosis even
when challenged with the profibrotic agent bleomycin (Huang
et al., 1996; Munger et al., 1999). Analysis of gene expression
in the lungs of bleomycin-treated mice suggests that lack of fi-
brosis in the 
 
 
 
6
 
-null mice is a consequence of decreased TGF-
 
 
 
activity because the overwhelming majority of TGF-
 
 
 
 re-
sponsive genes up-regulated in control mice are not increased
in the 
 
 
 
6
 
-null animals (Kaminski et al., 2000). The mecha-
nism of integrin-mediated latent TGF-
 
 
 
 activation is not well
understood. However, a direct interaction between 
 
 
 
v
 
 
 
6
 
 and
the RGD amino acid sequence present in LAP is required, as
mutation of this sequence to RGE eliminates activation. Im-
portantly, integrin binding by itself to latent TGF-
 
 
 
 is not suf-
ficient to activate TGF-
 
 
 
 as neither soluble 
 
 
 
v
 
 
 
6,
 
 LAP-
 
 
 
1–
binding to integrins 
 
 
 
V
 
 
 
1
 
, 
 
 
 
v
 
 
 
3
 
 (Munger et al., 1998), nor
 
 
 
8
 
 
 
1
 
 (Lu et al., 2002) activates latent TGF-
 
 
 
1.
Characterization of the mechanisms controlling the libera-
tion of TGF-
 
 
 
 from its latent complex is central to un-
derstanding TGF-
 
 
 
 action. Although several activators
(proteases, TSP-1, integrins) of latent TGF-
 
 
 
 have been
identified, the molecular basis for TGF-
 
 
 
 activation remains
only partially understood (Munger et al., 1997; Annes et al.,
2003). For instance, there is strong evidence that LTBP
plays an important role in protease-mediated latent TGF-
 
 
 
activation as both inhibitors of tTGase (Kojima and Rifkin,
1993) and antibodies raised against LTBP-1 block activation
of latent TGF-
 
 
 
 in several settings (Flaumenhaft et al.,
1993; Nakajima et al., 1997; Gualandris et al., 2000). How-
ever, the function of LTBP in these systems is unclear. Un-
like protease-mediated latent TGF-
 
 
 
 activation, 
 
 
 
v
 
 
 
6-
mediated latent TGF-
 
 
 
 activation was reported not to require
LTBP (Munger et al., 1999) based upon failure of anti-
LTBP antibodies to block 
 
 
 
v
 
 
 
6
 
-mediated activation. How-
Figure 1.  V 6-mediated latent TGF-  activation of SLC and 
TGF- 1 C:S. (A) The TGF-  large latent complex (LLC). The LLC is 
comprised of TGF-  (black), LAP (red) and LTBP. TGF-  and LAP 
are proteolytically processed at the site indicated by the arrowhead. 
LAP and LTBP are joined by disulfide bonds (light blue lines). The 
LLC is covalently linked by tTGase to the ECM via a glutamine-lysine 
isopeptide bond (green) near the NH2 terminus of LTBP. The hinge 
domain (arrow) of LTBP is a protease-sensitive region. (B) TGF- 1
 /  
cells that express the  -integrin subunit (TGF- 
 / / 6 cells) were 
co-cultured with TMLC that produce luciferase in response to TGF- . 
Co-cultures contained either no addition or recombinant SLC 
(200 ng/ml). After 16–24 h, cell lysates were collected and luciferase 
activity measured. The errors bars represent the SEM from a single 
experiment performed in duplicate. This experiment was repeated 
multiple times with similar results. (C) TGF- 
 / / 6 cells were 
transfected with an empty vector, TGF- 1 cDNA, or TGF- 1 C:S 
cDNA and co-cultured with TMLCs for 16–24 h. The cell lysates 
were assayed for luciferase activity. (D) The transfected cells (C) 
were also used to generate conditioned media (CM) for 16–24 h. 
CM was collected, heated to 80 C for 10 min, diluted 10-fold, and 
added to TMLC. In separate wells, various concentrations of recom-
binant TGF-  were added to TMLCs to generate a TGF-  standard 
curve. The amount of TGF-  present in the CM was determined 
based upon the standard curve. Luciferase assays were performed in 
triplicate and the SD of a single experiment is shown. (C and D) The 
errors bars represent the SD of a single experiment that was performed 
in triplicate. These experiments were repeated multiple times with 
similar results. (E) The CM generated by the transfected cells was 
also used for Western blotting. Protein bands were revealed with 
Vb3A9 (anti-LAP).LTBP-1 in integrin-mediated TGF-  activation | Annes et al. 725
ever, it is possible that the roles of LTBP in protease- and
integrin-mediated activation are distinct and cannot be
inhibited in the same way. An important next step in under-
standing latent TGF-  activation is to elucidate the func-
tion(s) of LTBP. Here, we present experimental results that
define domains of LTBP-1 that are required for integrin-
mediated latent TGF-  activation, demonstrate an isoform
(LTBP-1) specific function and gain insight into the mecha-
nism of LTBP-1 regulation of TGF-  generation.
Results
 V 6-mediated activation of latent TGF-  requires LTBP
Our previous results suggesting that  V 6-mediated activation
of latent TGF-  involved the RGD of LAP led us to test if re-
combinant SLC would be activated when added to TGF- 1
null cells engineered to express the integrin  V 6 (TGF- 
 / /
 6 cells). To test this, TGF- 
 / / 6 cells were co-cultured
with transformed mink lung epithelial cells (TMLC), which
produce luciferase in the presence of TGF- , and recombinant
SLC added to the culture. At the end of the incubation, the
monolayer was scraped and the amount of luciferase deter-
mined. Surprisingly, even when TGF- 
 / / 6 cells were incu-
bated with rSLC at a final concentration of 200 ng/ml, which
is 100-fold the typical endogenously secreted concentration of
latent TGF- , only a modest increase in active TGF- , as de-
termined by luciferase levels, was observed (only twofold above
the background; Fig. 1 B). By contrast, a significant increase in
TGF-  generation occurred when the same cells were trans-
fected with an expression vector encoding the entire TGF- 
precursor (Fig. 1 C, compare vector with TGF- 1) and subse-
quently co-cultured with TMLC, even though the total latent
TGF-  concentration in the medium was only  700 pg/ml
TGF-  (Fig. 1 D, TGF- 1; Annes et al., 2002). These results
indicate that rSLC is a poor substrate for  V 6-mediated acti-
vation. Two interpretations as to why rSLC is inefficiently ac-
tivated are: (1) the mechanism of  V 6-mediated activation
limits cells to modifying only the TGF-  that they secrete; or
(2) LTBP is a required component of this activation mecha-
nism and therefore SLC is not a substrate. To distinguish be-
tween these possibilities, we took advantage of a form of TGF-
 1 (Saharinen et al., 1996) that contains a point mutation in
the LAP coding sequence (C33S) that prevents disulfide bond-
ing to the third CR (CR3) domain of LTBP-1S. When TGF-
 
 / / 6 cells were transfected with an expression vector en-
coding either wild-type TGF-  or the mutant form of TGF- 
(TGF-  C:S), only wild-type TGF-  formed LLC, although
TGF-  C:S LAP was well secreted (Fig. 1 E). These constructs
contain coding sequence for TGF-  and its propeptide and
should therefore code for latent TGF- . The high secretion
level of this protein probably reflects the absence of the other-
wise unpaired C33. Assays for TGF-  generation by these
transfected cells with a TGF-  reporter cell line revealed that
cells transfected with wild-type TGF- 1 cDNA produced sig-
nificant amounts of active TGF- , but TGF- -C:S trans-
fected cells only formed active TGF-  at levels comparable to
background (Fig. 1 D). Addition of an  V 6-blocking anti-
body (10D5; 15  g/ml) prevented TGF-  generation (un-
published data). The failure to activate TGF-  C:S did not
reflect poor secretion of this mutant protein as these cells
consistently secreted more total TGF-  than the wild-type
TGF-  transfected cells (Fig. 1 D). These results led us to fa-
vor the hypothesis that  V 6-mediated activation of latent
TGF-  requires a covalent interaction between LAP and
LTBP.
An LTBP-1–derived minimal TGF- –binding construct 
does not support  V 6-mediated activation of latent TGF- 
A covalent interaction between LTBP and LAP might be re-
quired for  V 6-mediated activation because binding to LTBP
may alter the structure of the SLC in a way that permits inte-
grin-mediated activation, whereas in the absence of LTBP the
SLC complex adopts a conformation unsuitable for integrin-
mediated activation. If this hypothesis is correct, the small re-
gion of LTBP that covalently binds LAP might be sufficient to
support  V 6-mediated latent TGF-  activation. To test this
supposition, we used an LTBP-1S–derived construct that en-
codes only the LAP binding domain of LTBP (CR3) plus the
Figure 2. Structure and expression of LTBP constructs. A number 
of LTBP-1S–derived expression constructs are used throughout this 
paper. (A) These constructs are schematically represented with their 
name, description, and ability to support latent TGF-  activation 
given. The highly modular structure of LTBP-1 is represented with 
EGF-like domains in red (noncalcium binding) and black (calcium 
binding), and CR domains shown in yellow (hybrid) and blue. The 
mutated CR3 domain of construct XIV (light blue) has been altered 
to resemble the non TGF- –binding CR3 domain of LTBP-2. (B) The 
expression constructs shown schematically in A were cotransfected 
with simian proTGF- 1 into CHO cells and the conditioned media 
were collected and probed with Ab39 (anti–LTBP-1S), Vb3A9 
(anti-LAP) and anti-HA, as appropriate, to demonstrate secretion 
and complex formation with LAP.726 The Journal of Cell Biology | Volume 165, Number 5, 2004
flanking EGF-like repeats (EGF13 and 14; ECR3E, Fig. 2 A;
Gleizes et al., 1996). The EGF-like domains are not re-
quired for LAP binding but are included to enhance expres-
sion of the protein product. As a control, we generated a
similar expression construct that encodes CR4, which does
not bind LAP (Gleizes et al., 1996), plus its flanking EGF-
like domains (EGF15 and 16; Fig. 2 A, ECR4E). The effect
of these expression constructs on latent TGF-  activation
was tested by using CHO 6 cells transduced with ECR3E,
ECR4E or empty virus (Fig. 3 A). In this experiment, the
CHO 6 cells (as opposed to the TGF- 1
 / / 6 cells in Fig.
1) activate their endogenously produced latent TGF-  (Fig.
3 A). Thus, the background levels of active TGF-  are
higher than those observed in Fig. 1. Contrary to our hy-
pothesis, CHO 6 cells that expressed ECR3E demonstrated
decreased latent TGF-  activation ( 50%), rather than un-
changed or increased latent TGF-  activation compared
with mock-transduced and ECR4E-transduced cells (Fig. 3
A). The empty vector and the ECR4E expression construct
had similar effects on latent TGF-  activation.
The above results suggested that ECR3E blocked activa-
tion by preventing the formation of the LLC. To test this
possibility, we transiently transfected CHO 6, CHO 6/
ECR3E, and CHO 6/ECR4E cells with a full-length TGF- 
expression construct. The conditioned media generated
with these cells was collected and used to assess LLC forma-
tion by blotting with an anti-LAP antibody (Fig. 3 B).
Whereas empty virus-transduced cells and ECR4E-trans-
duced cells secreted both free LAP and LAP complexed with
LTBP (Fig. 3 B, vector and ECR4E-2HA), ECR3E-trans-
duced cells produced mostly LAP–ECR3E complex and
barely detectable levels of LAP–LTBP complex (Fig. 3 B).
Therefore, the inhibitory effect of ECR3E on latent TGF- 
activation correlated with a decrease in the formation of
LLC. These results suggested that the function of LTBP in
 V 6-mediated activation cannot be substituted by a mini-
mal TGF-  binding cassette.
A fragment of the hinge domain rescues ECR3E function
Based upon the preceding results that (1)  V 6-mediated ac-
tivation requires a covalent interaction between LTBP and
latent TGF-  and that (2) ECR3E is not sufficient to sup-
port  V 6-mediated activation, we suspected that an addi-
tional domain of LTBP-1S is required for latent TGF- 
activation by this mechanism. To define the domain of
LTBP-1 involved in the activation process by a gain of func-
tion rather than a loss of function method, we required an
experimental system in which  V 6-mediated activation of
latent TGF-  was ineffective unless rescued by the introduc-
tion of LTBP-1S. The development of such a system was
hindered by endogenous LTBP expression in every cell line
tested (unpublished data). However, we circumvented this
problem by taking advantage of CHO- 6 cells that stably
express ECR3E. These cells have an impaired ability to acti-
vate latent TGF-  due to a block in LLC formation (similar
to Fig. 3 B). Therefore, by transiently transfecting LTBP-1S
into CHO- 6/ECR3E cells, we could restore LLC forma-
tion and  V 6-mediated latent TGF-  activation.
We mapped the LTBP-1S domains required for  V 6-
mediated latent TGF-  activation by testing expression con-
structs with increasing NH2-terminal deletions (Fig. 2 A,
constructs II–VII). The initial results of these experiments
indicated a requirement for a region between amino acids
216 and 342 (CR1 and EGF2; Fig. 4 A) based upon the fact
that construct III supports integrin-mediated activation, but
construct IV, which lacks CR1 and EGF2, does not. Further
NH2-terminal deletion of LTBP-1 (constructs VI and VII)
did not restore  V 6-mediated activation of latent TGF- 
(Fig. 4 A and not depicted). We attempted to identify the
minimal LTBP-1S–derived construct that sustained activa-
tion (Fig. 4 B) by fusing the NH2-terminal portion of
LTBP-1S (construct VIII, amino acids 1–529) to ECR3E.
This construct retained the ability to bind latent TGF- 
(Fig. 2 B), although the LTBP lacked the long EGF-like
stretch and the COOH-terminal portion of LTBP-1S. Sur-
prisingly, this construct rescued latent TGF-  activation
(Fig. 4 B, construct VIII). Further NH2-terminal deletions
of construct VIII (constructs IX, X, and XII) did not prevent
latent TGF-  activation (Fig. 4 B). Indeed, a short amino
acid sequence (amino acids 402–529) derived from the
hinge domain, when fused to ECR3E, was sufficient to re-
store activation by CHO- 6/ECR3E cells (Fig. 4 B, con-
struct XII). The apparent discrepancy between the results of
the NH2-terminal deletion study that implicates amino acids
216–342 (CR1 and EGF2) and the minimal domain experi-
ment that identifies amino acids 402–529 (hinge) as neces-
sary for latent TGF-  activation raises the possibility that
amino acids 216–342 modulate the function of the hinge
domain by interacting with a distal portion of LTBP-1S, al-
though other explanations are possible.
To identify the required hinge domain, two additional
LTBP-1–derived constructs were synthesized (Fig. 2 A, con-
structs XI and XIII) and tested. The results revealed that
amino acids 402–449 (construct XIII), but not amino acids
449–529 (construct XI), from the hinge domain are suffi-
cient to rescue ECR3E function (Fig. 4 C). Thus, the NH2-
terminal portion of the hinge domain functions in a capacity
that is not mimicked by the COOH-terminal portion of the
Figure 3. Affect of ECR3E on  V 6-mediated latent TGF-  activation 
and LLC formation. CHO/ 6 cells were transduced with empty, 
ECR3E- or ECR4E-expressing viruses. (A) The transduced cells were 
co-cultured with TGF- -reporter TMLCs for 16–24 h before harvesting 
cell lysates and measuring luciferase activity. Experiments were 
performed in triplicate and the SDs of a single experiment are given. 
The errors bars represent the SD of a single experiment that was 
performed in triplicate. This experiment was repeated multiple 
times with similar results. (B) The transduced cells were transiently 
transfected with a TGF- 1 cDNA expression vector and allowed to 
generate CM for 16–24 h. The media were used for Western blotting. 
The reactive bands were revealed with an anti-LAP antibody (Vb3A9).LTBP-1 in integrin-mediated TGF-  activation | Annes et al. 727
hinge domain. In addition, we wanted to demonstrate that
the ability of construct XIII ( N402-449-ECR3E) to sup-
port  V 6-mediated latent TGF-  activation required a co-
valent interaction between latent TGF-  and the CR3 do-
main. To eliminate the disulfide interaction between LAP
and the CR3 domain, we took advantage of the fact that the
CR3 of LTBP-2 does not covalently bind LAP because of a
two amino acid deletion compared with LTBP-1 (Saharinen
and Keski-Oja, 2000). By deleting the phenylalanine and
proline at positions 1060 and 1061 in the CR3 domain of
construct XIII, such that it resembled the CR3 domain of
LTBP-2, we generated construct XIV that fails to complex
with latent TGF-  (Fig. 2 A; see Materials and methods; for
review see Saharinen and Keski-Oja, 2000). As anticipated,
construct XIV failed to support  V 6-mediated latent TGF- 
activation (Fig. 4 C). Thus, amino acids 402–449-ECR3E
are sufficient to fulfill the function of LTBP-1S in  V 6-
mediated latent TGF-  activation, and this function re-
quires covalent association between LAP and ECR3E.
Next, we sought to determine if regions of LTBP-1S other
than the hinge domain could support integrin-mediated ac-
tivation. To accomplish this, we tested a mutant form of
LTBP-1 that lacked amino acids 402–449 for the ability to
support activation (Fig. 2 A, construct I). Indeed, construct
I failed to support  V 6-mediated activation (Fig. 5 B). In-
terestingly, the hinge domain of LTBP-1 is not conserved
among the other LTBP isoforms (Fig. 5 A). This fact raised
the possibility that LTBP-1 performs a function that is not
fulfilled by the other LTBP isoforms. To test this hypothe-
sis, we transfected CHO-ECR3E cells with an LTBP-3 ex-
pression construct and measured latent TGF-  activation
(Fig. 5 B). Despite the fact that LTBP-3 was secreted in
complex with latent TGF-  at levels similar to LTBP-1 (Fig.
5 C, compare LTBP-1S with LTBP-3 [LTBP1 403-449]),
LTBP-3 did not support latent TGF-  activation (Fig. 5 B).
As a further test of possible isoform specificity, an LTBP-3
expression construct in which the native hinge domain was
replaced with that of LTBP-1 (LTBP-3 with LTBP-1 hinge)
was tested for the ability to support  V 6-mediated activa-
tion. Strikingly, LTBP-3 with LTBP-1 hinge supported
TGF-  generation (Fig. 5 B). This result indicates that the
hinge domain of LTBP-1 confers an isoform-specific func-
tion within the LTBP family.
 V 6-mediated activation requires fixed latent TGF- 
Previous work in our laboratory has implicated the NH2-ter-
minal portion of LTBP-1 in matrix incorporation of LTBP-1
(Nunes et al., 1997). This finding led us to test the possi-
bility that amino acids 402–449 are capable of targeting the
latent TGF-  complex to the ECM. CHO K7 cells were sta-
bly transduced with either PMX empty virus, construct XI,
or construct XIII, subsequently transfected with latent TGF- 
cDNA, and allowed to synthesize a matrix for 24 h. The
cells were removed with EDTA, and the amount of TGF- 
incorporated into the ECM was measured (see Materials and
methods). Whereas construct XI reduced ECM targeting of
TGF-  two- to threefold, construct XIII supported ECM
association of latent TGF-  similar to empty virus-trans-
duced cells (unpublished data). (Similar results were ob-
tained with 2T3 and SW480 cells; unpublished data.) This
result is consistent with our hypothesis that amino acids
402–449 are sufficient for ECM association.
The cosegregation of two activities for amino acids 402–
449 of LTBP-1, namely support of latent TGF-  activation
and ECM association, led us to suspect that fixation of la-
tent TGF-  is required for  V 6-mediated latent TGF-  ac-
Figure 4. LTBP-1S–derived expression constructs rescue TGF-  
activation. (A) CHO-  6/ECR3E cells were cotransfected with NH2-
terminal deletion constructs and wild-type TGF- 1 before co-culture 
with TGF-  reporter TMLCs. After 16–24 h, the cell lysates were 
collected and luciferase activity measured. Similar experiments were 
conducted with additional LTBP-1S–derived expression constructs 
in B and C. In C, the size of the active hinge region (green) has been 
enlarged relative to other sequences for illustration purposes. In all 
cases, secretion of the transfected constructs and TGF-  complex 
formation was demonstrated (not depicted). Experiments were 
performed in triplicate. The error bars represent the SD from a single 
experiment.728 The Journal of Cell Biology | Volume 165, Number 5, 2004
tivation. According to this hypothesis, expression of the
minimal TGF-  binding construct, ECR3E, blocks in-
tegrin-mediated activation by preventing LLC formation
thereby disrupting localization of the latent TGF-  com-
plex. Therefore, we reasoned that artificial targeting of
ECR3E-bound latent TGF-  to the vicinity of the ECM
should restore  V 6-mediated latent TGF-  activation. To
test this prediction, we took advantage of the fact that the
ECR3E constructs encode tandem COOH-terminal HA
epitopes. Wells of a 96-well microtiter plate were either
mock coated or anti-HA Ab coated (25  g/ml). These wells
were subsequently used to test latent TGF-  activation by
CHO K7 cells engineered to express (1)  6 cDNA (Fig. 6 A,
bars 1 and 5), (2) ECR3E and  6 cDNAs (Fig. 6 A, bars 2
and 6), (3) ECR3E cDNA (Fig. 6 A, bars 3 and 7), or (4)
empty vectors (Fig. 6 A, bars 4 and 8). The  6-expressing
cells activated their endogenous latent TGF-  when plated
on either surface (Fig. 6 A, bars 1 and 5). However, by com-
paring bars 2 and 6 in Fig. 6 A, it is clear that the CHO-
ECR3E/ 6 cells demonstrate an enhanced (approximately
four times) activation of latent TGF-  on wells coated with
anti-HA Ab compared with mock-coated wells. In fact,
on mock coated wells CHO-ECR3E/ 6 activated approxi-
mately half as much latent TGF-  as CHO- 6 cells (Fig. 6
A, compare bar 1 with bar 2); on anti-HA Ab-coated wells
CHO-ECR3E/ 6 cells activated approximately two times
more latent TGF-  than CHO- 6 (Fig. 6 A, compare bar 5
with bar 6). Additional controls demonstrate that expression
of both ECR3E and  V 6 are required for enhanced activa-
tion on anti-HA Ab-coated wells (Fig. 6 A, bars 3, 4, 7, and
Figure 5. Activation and LLC formation of 
LTBP-1S and LTBP-3. (A) Alignment of the hinge 
domains of LTBP-1, -2, -3, and -4 using MAP 
(http://searchlauncher.bcm.tmc.edu/multi-align/
multi-align.html). Amino acids 403–449 of LTBP-1S 
are overlined. The boxed amino acid sequence 
identifies a putative GAG-binding sequence. 
(B) CHO- 6/ECR3E cells were cotransfected with 
either full-length TGF- 1 and LTBP-1S–derived 
expression constructs or LTBP-3–based expression 
constructs before co-culture with TGF-  reporter 
TMLCs. After 16–24 h, cell lysates were harvested 
and luciferase activity measured. The error bars 
represent the SD of a single experiment that was 
performed in triplicate. This experiment was 
repeated multiple times with similar results. 
(C) Conditioned media from the same transfected 
cells were collected and subjected to Western 
blotting using Vb3A9 to reveal reactive protein 
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8). We also observed a direct relationship between the HA
Ab-coating concentration and TGF-  generation by CHO-
ECR3E/ 6 cells (Fig. 6 B). In all cases, the generation of ac-
tive TGF-  was blocked by an  V 6-specific blocking Ab
(Fig. 6 B). Similar results were obtained with SW-480 cells
(not depicted). These and the previous results suggest that
LTBP-1S–derived expression constructs that support  V 6-
mediated activation do so because they effectively localize la-
tent TGF- , whereas constructs that fail to support activa-
tion do so because they cannot associate with the ECM.
An extension of the hypothesis that localization is required
for   V 6-mediated latent TGF-  activation is that latent
TGF-  secreted and deposited in the ECM by one cell can
be activated by a second cell. To test this prediction, we al-
lowed CHO cells engineered to express either LTBP-1S or
ECR3E to generate a matrix for 48 h. The matrix-producing
cells (CHO-LTBP-1S and CHO-ECR3E cells) were re-
moved and latent TGF- 1 activation measured by co-cul-
ture (Fig. 7). These cell types were selected because they do
not efficiently activate endogenously produced latent TGF- 
(Fig. 3 A and not depicted). Both SW480-ECR3E/ 6 and
CHO-ECR3E/ 6 cells activate TGF-  when placed on a
matrix produced by CHO-LTBP-1 cells. If these cells are
plated on a matrix produced by CHO-ECR3E cells, consid-
erably less TGF-  is formed (Fig. 7). This decrease in active
TGF-  presumably represents the diminished amount of la-
tent TGF-  incorporated into the matrix in the presence of
ECR3E. This result indicates that latent TGF-  in the form
of the LLC can be usefully stored and subsequently activated
in the ECM.
Discussion
LTBPs regulate TGF-  action through participation in se-
cretion (Miyazono et al., 1991), ECM localization (Taipale
et al., 1992, 1994b), and activation (Flaumenhaft et al.,
1993; Nakajima et al., 1997; Gualandris et al., 2000) of la-
tent TGF- . How these distinct functions of LTBP relate to
one another is not understood. Using  V 6-mediated latent
TGF-  activation as the model system, we have investigated
the function of LTBP by exploring the relationship between
localization and activation of latent TGF- . Several lines of
evidence support the hypothesis that  V 6-mediated latent
TGF-  activation requires LTBP to localize and fix latent
TGF- . First, recombinant SLC, which lacks LTBP, is not
an effective substrate for activation, whereas latent TGF- 
incorporated into the ECM by one cell may be used by an-
other cell at a later time. Second, TGF-  that cannot co-
valently interact with LTBP fails to be activated by  V 6.
Third, a minimal TGF- –binding cassette (ECR3E), de-
rived from LTBP-1S, that cannot bind the ECM obstructs
 V 6-mediated activation. Fourth, activation of ECR3E-
bound latent TGF-  can be accomplished through artificial
localization and fixation of this complex to the pericellular
environment.
The requirement of LTBP-dependent localization of la-
tent TGF-  for activation suggests that TGF-  activity is
regulated not only by the expression of latent TGF-  and an
activator, but also by the different forms of LLC, the avail-
ability of a binding partner and the supply of ECM-stored
latent TGF- . For instance, removal of the NH2-terminal
region of LTBP with plasmin generates a form of LTBP that
resembles platelet LTBP and fails to be incorporated into
the ECM (Taipale et al., 1994a). Consistent with our hy-
pothesis, expression constructs that encode forms of LLC
similar to platelet LLC (Fig. 2 A, constructs V, VI, VII) re-
Figure 6. Activation of artificially localized latent TGF- . (A) CHO 
cells that stably express  6-integrin (bars 1 and 5),  6-integrin and 
ECR3E (bars 2 and 6), ECR3E (bars 3 and 7), or untransfected (bars 4 
and 8) were co-cultured with TMLCs on mock-coated or HA-antibody–
coated wells. After 16–24 h, cell lysates were collected and assayed 
for luciferase activity. (B) The wells of a 96-well microtiter plate 
were coated with an anti-HA or control antibody, or anti- v 6 at 
various concentrations. CHO-ECR3E/ 6 cells and TMLCs were 
co-cultured on these wells. After 16–24 h, the cell lysates were 
collected and the luciferase activity measured. Each experimental 
condition was performed in triplicate. The SD from a single experi-
ment is shown.
Figure 7. Activation of ECM deposited latent TGF- . CHO cells 
stably transfected with ECR3E or LTBP-1S (5   10
4) were plated in a 
96-well plate for 48 h before removal with PBS/20 mM EDTA. SW480-
ECR3E/ 6 or CHO-ECR3E/ 6 cells and TMLCs were added to these 
wells. After 16–24 h, cell lysates were collected and luciferase 
activity measured. All experimental conditions were performed in 
triplicate. The SD from a single experiment is shown.730 The Journal of Cell Biology | Volume 165, Number 5, 2004
sult in protein products that fail to support activation in our
system (Kanzaki et al., 1990; Miyazono et al., 1991). In ad-
dition, the various isoforms of LTBP may differentially reg-
ulate TGF-  activity, as latent TGF-  bound to LTBP-3 is
not a substrate for  V 6-mediated activation. It is interesting
that the greatest degree of sequence divergence between
LTBP-1 and LTBP-3 is within their hinge domains and that
it is this region of the molecule that confers an LTBP-1–spe-
cific function. This specificity for LTBP-1 hinge domain in
 V 6-mediated activation of latent TGF-  suggests that the
hinge domains of LTBP-3, -2, and -4 may have distinct
functions and cannot substitute for each other under all con-
ditions. Furthermore, the activities of different LTBP iso-
forms and splice variants may relate to their distinct patterns
of intra- and extracellular localization.
Our work indicates that processes that influence matrix
deposition of latent TGF-  are predicted to affect  V 6-
dependent TGF-  generation both positively and negatively.
Interestingly, matrix association of latent TGF-  may differ-
entially influence protease-mediated activation versus  V 6-
mediated activation. Protease-mediated latent TGF-  acti-
vation may require release of latent TGF-  from the ECM
for subsequent cell surface localization and activation (Flau-
menhaft and Rifkin, 1992a; Nunes et al., 1997), whereas
 V 6-mediated latent TGF-  activation may occur while la-
tent TGF-  is fixed. To better understand latent TGF-  ac-
tivation and TGF-  activity in general, it will be important
to answer questions such as: (1) Is LTBP required for other
activation mechanisms? (2) What are the roles of the various
LTBP isoforms in these processes? (3) How is activation of
SLC accomplished/regulated?
Mapping identified a portion of the hinge domain, amino
acids 402–449, and the TGF- –binding domain as the
minimal LTBP-1–derived domains that support  V 6-medi-
ated latent TGF-  activation. (The relationship of the hinge
domain and the tTGase cross-linking site is unclear.) This
hinge region may function by targeting latent TGF-  to an
extracellular location. The hinge sequence of LTBP-1 con-
tains a putative heparin-binding site that might facilitate
ECM or cell surface targeting of the latent TGF-  complex
(Oklu et al., 1998; Dallas et al., 2002; Isogai et al., 2003).
Currently, we are trying to identify the hinge domain bind-
ing partner.
To understand the mechanism of  V 6-mediated activa-
tion, it is necessary to appreciate the function of LTBP in
this process. The results presented here suggest that LTBP
promotes  V 6-mediated activation by both concentrating
and fixing the latent complex. The requirement for inte-
grin–cytoskeleton interaction for latent TGF-  activation
suggests that force generation by the integrin may be neces-
sary. Indeed, the mechanism by which integrins generate
force may explain why fixation of latent TGF-  in the
ECM is important: integrin-dependent force generation
across the cell membrane increases with increasing resis-
tance (Choquet et al., 1997). We hypothesize that fixation
of latent TGF-  provides resistance to integrin pulling, al-
lowing focal contact reinforcement and force generation
sufficient to release TGF-  from latency. Our current con-
ception of  V 6-mediated latent TGF-  activation is repre-
sented schematically in Fig. 8. In this model, LTBP-1 but
not LTBP-3 is able to fix the latent complex to the ECM.
Consequently, the LTBP-1–TGF-  complex is incorpo-
rated into the ECM and, therefore, when bound by  V 6,
promotes focal adhesion formation, force generation, and
release of TGF-  from the latent complex. By contrast, in-
tegrin binding to latent the LTBP-3–TGF-  complex does
not result in adhesion complex formation, force generation,
and latent TGF-  activation. Consistent with this model,
we predict that protease-mediated release of a soluble latent
TGF-  restricts TGF-  generation by the integrin  V 6.
Thus, the function of LTBP-1 in  V 6-mediated latent
TGF-  activation is to concentrate and fix latent TGF-  so
that integrin pulling is opposed. This resistance alters the
conformation of LAP and releases TGF- . The necessity of
localization and force generation provide mechanisms for
spatially restricting TGF-  activity and raises the threshold
of latent TGF-  activation to limit inappropriate cytokine
activity.
Materials and methods
Cell lines and reagents
CHO K7 cells were obtained from the ATCC. CHO-ECR3E-2HA, CHO-
ECR4E-2HA, and CHO-LTBP cells were generated by stable transfection of
CHO K7 cells with a pcDNA3 (Invitrogen) expression vector containing
ECR3E-2HA, ECR4E-2HA, and LTBP-1S coding sequences, respectively.
The generation of these expression constructs is described below. Stable
cell lines were selected with G418 Sulfate (Mediatech) and cloned by lim-
iting dilution. CHO-ECR3E-2HA/ 6, CHO-ECR4E-2HA/ 6 and CHO-LTBP/
 6 cells were generated by retroviral transduction of the stable lines with
PMX/ 6 retrovirus. Retroviral production was accomplished by using the
Pantropic Retroviral Expression System following the manufacturer’s in-
structions (CLONTECH Laboratories, Inc.). TMLC, which produce lu-
ciferase in response to TGF- , were used as described previously (Abe et
al., 1998). TGF- 1
 /  liver fibroblasts were a gift from A. Roberts (National
Institutes of Health, Bethesda, MD) were stably transfected with either
pCDNA3.1/Hygro ( ) (TGF- 1
 /  cells) or pCDNA3.1/Hygro ( ) contain-
Figure 8. Schematic representation of  V 6-mediated latent TGF-  
activation. TGF-  is secreted in a complex with a variety of LTBP 
isoforms and splice variants. The highly variable primary sequence 
of the hinge domain localizes latent TGF-  in the extracellular 
environment. Importantly, the hinge domain of LTBP-1 functions in 
a capacity that is not replicated by the hinge domain of LTBP-3. 
Once latent TGF-  is fixed in the ECM, the integrin  V 6 binds LAP 
and generates a retractile force. The magnitude of this force is related 
to the resistance garnered through association of the latent complex 
with the ECM. Once the force generated by the integrin exceeds a 
threshold, biologically active TGF-  is made available. Release of 
the latent complex from its association with the ECM, for example 
by proteases, is predicted to prevent  V 6-mediated latent TGF-  
activation as integrin retraction will no longer be resisted.LTBP-1 in integrin-mediated TGF-  activation | Annes et al. 731
ing the  6-subunit cDNA (TGF- 1
 / / 6 cells) as described previously
(Annes et al., 2002).  6-Integrin transfected SW480 (SW480/ 6 cells) and
CHO cells (CHO/ 6 cells) were a gift from D. Sheppard (University of Cal-
ifornia, San Francisco [UCSF], San Francisco, CA; Weinacker et al., 1994).
SW480-ECR3E-2HA/ 6 were generated by retroviral transduction of
SW480/ 6 cells with PMX-ECR3E-2HA.
Cells were cultured in Dulbecco’s minimum essential medium (DMEM)
containing 10% heat-inactivated FCS. Mouse mAb HA.11 against the HA
epitope was purchased from Covance Research Products (Berkeley Anti-
body Company). VB3A9 is an mAb directed against the LAP portion of hu-
man TGF- 1 (Munger et al., 1998). Ab39, rabbit polyclonal antisera raised
against platelet LTBP-1, was provided by C.-H. Heldin (Ludwig Institute for
Cancer Research, Uppsala, Sweden). Mouse anti- V 6 mAb 10D5 (Huang
et al., 1998) was a gift of D. Sheppard. Recombinant simian TGF- 1 LAP
was produced as described previously (Munger et al., 1998). All molecular
biology enzymes were purchased from Roche Diagnostics. Recombinant
human TGF- 1 SLC was purchased from R&D Systems.
Constructs and vectors
pcDNA3 and pSecTag 2C vectors were obtained from Invitrogen. PMX ret-
roviral vector was provided by T. Kitamura (Tokyo University, Tokyo, Ja-
pan). Simian TGF- 1 cDNA was a gift from R. Derynck (UCSF). Human
TGF- 1 C33S cDNA was a gift from J. Keski-Oja (University of Helsinki,
Helsinki, Finland). Human LTBP-1S cDNA (pSV7d-BP13) was a gift of K.
Miyazono and C.-H. Heldin (Ludwig Institute for Cancer Research).  6-
Integrin cDNA was a gift of D. Sheppard.
Generation of pcDNA3-LTBP-1S and pcDNA3- N441 expression vec-
tors was described previously (Nunes et al., 1997). In brief, pcDNA3-
LTBP-1S was constructed by fusing the DraI–DrI fragment of pSV7d-BP13
(nucleotides 68–4543) in frame with the baculovirus glycoprotein GP67
signal sequence in pcDNA3. Similarly, pcDNA3- N441 was generated by
fusing the HpaI–DraI fragment (nucleotides 1414–4543) of pSV7d-BP13 in
frame with the GP67 signal sequence in the pcDNA3 vector.
The PCR primers and templates used for generation of the expression
constructs described below are given in Table I. The expression construct
pcDNA3-ECR3E-2HA (nucleotides 2872–3408) was generated by PCR am-
plification (primers 1, 2) using pcDNA3-LTBP-1S as the template. This PCR
product was fused to the BM40 signal sequence the pRcCMV/Ac7 vector
(gift of R. Timpl, Max-Plank Institute, Martinsried, Germany). The pRc-
CMV/Ac7–ECR3E vector was digested with HpaI–XbaI and an adapter cas-
sette coding for two copies of the HA-epitope was subcloned in frame and
downstream of the ECR3E coding sequence. The ECR3E-2HA coding se-
quence was subsequently transferred from pRcCMV/Ac7 to an intermedi-
ate vector (pKN185; gift of Y. Yamada, National Institutes of Health) using
an EagI digest of both vectors. The ECR3E-2HA coding sequence was sub-
sequently released from PKN185-ECR3E-2HA by a HindIII–BamHI digest
and subcloned into pCDNA3 (HindIII–BamHI) and pBluescript II KS 
(Strategene). ECR3E-2HA was transferred from pBluescript II KS  -ECR3E-
2HA (pBlue-ECR3E-2HA) to PMX (HindIII–NotI digest). To make PMX-
ECR4E-2HA, the ECR4E coding sequence was amplified (primers 3, 4)
using pcDNA3-LTBP-1S as the template and subcloned into the pBlue-
ECR3E-2HA vector backbone, which retained the BM40 signal sequence
and the 2HA epitopes. This was accomplished by SpeI–HpaI digest of both
the ECR4E PCR product and pBlue-ECR3E-2HA vector and ligation of the
digested ECR4E PCR product into the pBlue-ECR3E-2HA vector backbone.
ECR4E-2HA was subsequently transferred to the PMX retroviral vector by
HindIII–NotI digest of pBlue-ECR4E-2HA, purification of the ECR4E-2HA
insert, and ligation into similarly digested PMX retrovirus vector DNA.
A variety of constructs were synthesized using the technique of strand
overlap extension in which two separate PCR reactions (reactions 1 and 2)
were set up to generate overlapping DNA products that were subsequently
purified, mixed, and sewn together in a third PCR reaction (reaction
3). The extreme 5  and 3  primers from the first PCR reactions were
used in reaction 3. The expression vectors pcDNA3- C529/ECR3E-2HA
and pcDNA3- C412/ECR3E-2HA were constructed using strand overlap
extension PCR (primers 9/10, 11/12 and 13/14, 15/16, respectively) with
pcDNA3-LTBP-1S as the template. The products were digested with
EcoRI–NotI and ligated into similarly digested pcDNA3. Several NH2-ter-
minal deletion constructs were made by fusing PCR amplified portions of
LTBP-1S downstream and in frame with the murine Ig  -chain leader se-
quence present in the pSecTag2C vector (Invitrogen; pSecTag2C- N104
primers 17, 18; pSecTag2C- N216 primers 19, 18; pSecTag2C- N342:
primers 20, 18; pSecTag2C- N402 primers 21, 18 pSecTag2C- N441 prim-
ers 22, 18; pSecTag2C- N529 primers 23, 18). These PCR products
were  digested with NotI–XhoI and subcloned into similarly digested
pSecTag2C.
A number of LTBP-1S deletion constructs were made in pSecTag2C us-
ing strand overlap extension PCR reactions pSecTag2C- N216/ C529-
ECR3E-2HA (primers 24/25,11/12); pSecTag2C- N342/ C529-ECR3E-
2HA (primers 26/25, 11/12); pSecTag2C- N402/ C529-ECR3E-2HA
(primers 27/25, 11/12); pSecTag2C- N449/ C529-ECR3E-2HA (primers
28/25, 11/12). In all cases, the amplified products of reaction 3 were
NotII–XhoI digested before being subcloned into similarly digested
pSecTag2C vector. pSecTag2C- N402/ C449-ECR3E-HA L1→L2 was gen-
erated by two successive QuickChange Site-Directed Mutagenesis re-
actions (Stratagene). The first reaction deleted the phenylalanine and pro-
line (amino acids 1060 and 1061 of LTBP-1S) that are found in CR3 of
human LTBP-1 but not in CR3 of human LTBP-2. This was accomplished
using a sense primer (5 -GGGGAGATAACTGCGAAATCTGCCCGGTCT-
TGGGAACTGC-3 ) and an equivalent antiparallel primer. The second re-
action mutated the glutamate and isoleucine of human LTBP-1 CR3
(amino acids 1058 and 1059 of LTBP-1S) to aspartate and leucine, which
are found in the homologous region of human CR3 of LTBP-2. This was ac-
complished using a sense primer (5 -GGGGAGATAACTGCGACCTCTG-
CCCGGTCTTGGGAACTGC-3 ) and an equivalent antiparallel primer.
pSecTag2C– N402/ C449-ECR3E-HA was generated by PCR amplifica-
tion (primers 29, 30). The PCR fragment was digested with HindIII and
BamHI and cloned into a similarly digested pSecTag2C-ECR3E-HA vector.
pSecTag2C- N19/ C449-ECR3E-HA was constructed by PCR amplifica-
tion (primers 31, 32). The PCR product was digested with HindIII and
BamHI and cloned into similarly digested pSecTag2C-ECR3E-HA vector.
pcDNA-LTBP1  402-449 was constructed by PCR amplification (prim-
ers 33/34, 35/36) of 5  and 3  fragments that were digested (reaction 1,
ClaI–EcoRV; reaction 2, HpaI–EcoRI), purified and cloned into pcDN3-
LTBP-1S digested with ClaI–EcoRI. HA tagged versions of pcDNA3-LTBP-1,
-LTBP-1S- N402-449, and -LTBP- N402 were generated by digesting
these constructs with EcoRI–XbaI and cloning in a COOH-terminal HA
tagged amplified product from pcDNA3-LTBP-1S (primers 37, 38). PMX-
 N402/ C449-ECR3E-HA, PMX- N402/ C449-ECR3E-HA L1→2, and
PMX- N449/ C529-ECR3E-HA were generated by PCR amplification us-
ing the respective pSecTag2C vectors as templates (primers 39, 40). The
PCR products were digested with EcoRI–XhoI and cloned into PMX vector
digested with EcoRI–SalI. PMX- 6 retroviral vector was prepared by isolat-
ing the Pme digestion fragment of pHygrobeta6 and cloning into filled-in
EcoRI digested PMX virus (Annes et al., 2002). The LTBP-3 with the LTBP-1
hinge expression construct was synthesized by a series of strand-overlap
extension PCR reactions that sewed the LTBP-1 hinge domain into the
LTBP-3 coding sequence. First, overlapping PCR products derived from
LTBP-3 (upstream of the hinge domain) and LTBP-1 were synthesized sep-
arately (primers 41/42 and 43/44). These products were then combined to-
gether for reaction 3. A fourth PCR reaction was set up to generate an
LTBP-3–derived product (downstream of the hinge domain) that also over-
lapped with the LTBP-1 hinge domain (primers 45/46). This product was
combined with the product of reaction 3 and sewn together in a fifth PCR
reaction (primers 41/46). The product of this PCR reaction was digested
with EcoRV and Nru and cloned into similarly digested pcDNA3-LTBP-3.
All constructs were checked by automated sequencing.
TGF-  bioassays
TGF-  activation was measured using CHO cells stably transfected with an
ECR3E-2HA expression construct and the  6-integrin subunit (CHO-
ECR3E-2HA/ 6) subsequently transiently transfected with proTGF- 1 and
various LTBP-1S–derived cDNAs. Before transient transfection, test cells
were plated at 4   10
5 cells per 35-mm well in DMEM/10% FCS. After 16 h,
cells were transfected with the LTBP-1S expression constructs (1  g per
well) and the TGF- 1 expression construct (400 ng per well) using Lipo-
fectAMINE Plus. After 16 h, the cells were collected in 3 ml of DMEM/10%
FCS and replated in 96-well and 24-well plates (50 and 500  l per well,
respectively). TMLC (1.5   10
4) were added to the 96-well plates (final
volume, 100  l per well). When appropriate, 10D5 (20  g/ml) or LAP (100
 g/ml) was added to the co-culture. Conditioned media were generated in
the 24-well plate monocultures. After 16–24 h, TGF-  activation was as-
sessed by measuring luciferase activity in the cell lysates from co-cultures
(Abe et al., 1994). In addition, the conditioned media from monoculture
wells was collected after 16–24 h and analyzed by immunoblotting (Ab39
or HA.11) for secretion of the various LTBP forms as well as by TMLC as-
say for total TGF-  secretion by heat activating latent TGF-  (80 C for 10
min). The samples were incubated with TMLC overnight and luciferase ac-
tivity measured.
To test TGF- 1 SLC as a substrate for  V 6-mediated latent TGF-  acti-
vation, TGF- 1
 /  cells and TGF- 1
 / / 6 cells (1.5   10
4 cells per well)
were co-cultured with TMLC (1.0   10
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the presence of TGF- 1 SLC (0–200 ng/ml of TGF- 1 SLC). After 16–24 h,
luciferase activity in the cell lysates was measured. To test if  V 6-medi-
ated latent TGF-  activation requires TGF-  binding to LTBP, TGF- 1
 / /
 6 cells (8   10
4 cells per 35-mm well) were transiently transfected with
cDNAs encoding either wild-type human TGF- 1 (400 ng per well) or hu-
man TGF- 1C:S (400 ng per well). The establishment of co-cultures to
measure TGF-  activation and monocultures to measure total TGF-  se-
cretion was as described previously (Abe et al., 1994).
Table I. Construction of expression vectors
Description Primers
pCDNA3 LTBP-1S a gift from K. Miyazono and C-H. Heldin (Ludwig Institute for Cancer Research, Uppsala, Sweden)
pCDNA3 LTBP-1S  N441 described previously in Nunes et al., 1997
pCDNA3 ECR3E-HA PCR amplification: Reaction 1 (template   pCDNA3 LTBP-1S)
pBS ECR3E-HA primer 1: cggggatccactagtggatgtgaatgaatgtgaact
PMX ECR3E-HA primer 2: aacaagcactgcagtttcacagg; *A 3  HA epitope tag was added via ligation of an adapter cassette; 
5 -aacctacccctacgacgtgcccgactacgcctacccctacgacgtgcccgactacgcct; gaagatcttgattggaattccggccgt-3 
PMX ECR4E PCR amplification: Reaction 1 (template   pCDNA3 LTBP-1S) primer 3: 
cactagtggatatggatgaatgtcaagaccccagt; primer 4: 
gggtaggttaacagatcttcttcagaaataagtttttgttccacgtggaaacaggtcatcttggcagtatc
pcDNA3  C529-ECR3E-HA PCR amplification: Reaction 1 (template   pCDNA3 LTBP-1S); primer 9: 
atttacgaattcatggatactaagctgatgtgtttg; primer 10: cacattcattcacatcaggagctacttcaacaggcacaggagg; Reaction 2 
(template   pCDNA3 ECR3E); primer 11: gaagtagctcctgatgtgaatgaatgtgaactgctcagtgg; primer 12: 
tcaaatgcggccgctcaggcgtagtcgggcacgtcg
pcDN3  C412-ECR3E-HA PCR amplification: Reaction 1 (template   pCDNA3 LTBP-1S); primer 13: 
atttacgaattcatggatactaagctgatgtgtttg; primer 14: attcattcacatcgccagaaaccgtataaccc; Reaction 2 (template   
pCDNA3 ECR3E); primer 15: acggtttctggcgatgtgaatgaatgtgaactgc; primer 16: 
tcaaatgcggccgctcaggcgtagtcgggcacgtcg
pSecTag2C LTBP-1S  N104 PCR amplification: Reaction 1 (template   pCDNA3 LTBP-1S); primer 17: 
ctatcagcggccgcctcagatcccagtccatggtgcc; primer 18: tgtttactcgagactccaggtcactgtctttctctaaattcaagg
pSecTag2C LTBP-1S  N216 PCR amplification: Reaction 1 (template   pCDNA3 LTBP-1S); primer 19: 
ctatcagcggccgcctgtcattcctcacgtctaccc; primer 18: as above
pSecTag2C LTBP-1S  N342 PCR amplification: Reaction 1 (template   pCDNA3 LTBP-1S); primer 20: 
ctatcagcggccgcctccccctgtgatctcggaagagaaaggg; primer 18: as above
pSecTag2C LTBP-1S  N402 PCR amplification: Reaction 1 (template   pCDNA3 LTBP-1S); primer 21: 
ctatcagcggccgcctccccctgtgatctcggaagagaaaggg; primer 18: as above
pSecTag2C LTBP-1S  N441 PCR amplification: Reaction 1 (template   pCDNA3 LTBP-1S); primer 22: 
ctatcagcggccgcctactcatcctccacctctcccagcc; primer 18: as above
pSecTag2C LTBP-1S  N529 PCR amplification: Reaction 1 (template   pCDNA3 LTBP-1S); primer 23: 
ctatcagcggccgcctgcttctacgtctagtgccagcc; primer 18: as above
pSecTag 2C
 N216- C529-ECR3E-HA
PCR amplification: Reaction 1 (template   pcDNA3  C529-ECR3E-HA); primer 24: 
ctatcagcggccgcctgtcattcctcacgtctaccc; primer 25: cacattcattcacatcaggagctacttcaacaggcacaggagg; 
Reaction 2 (pcDNA3  C529-ECR3E-HA); primer 11/primer 12
pSecTag 2C
 N342- C529-ECR3E-HA
PCR amplification: Reaction 1 (template   pcDNA3  C529-ECR3E-HA); primer 26: 
ctatcagcggccgcctccccctgtgatctcggaagagaaaggg; primer 25: as above; Reaction 2 (pcDNA3  C529-ECR3E-
HA); primer 11/primer 12
pSecTag 2C
 N402- C529-ECR3E-HA
PCR amplification: Reaction 1 (template   pcDNA3  C529-ECR3E-HA); primer 27: 
ctatcagcggccgcctcctggtggaatgggttatacggtttctggcg; primer 25: as above; Reaction 2 (pcDNA3  C529-
ECR3E-HA); primer 11/primer 12
pSecTag 2C
 N449- C529-ECR3E-HA
PCR amplification: Reaction 1 (template   pcDNA3  C529-ECR3E-HA); primer 28: 
ctatcagcggccgcctaaggaagagccagtggaggccctgacc; primer 25: as above; Reaction 2 (pcDNA3  C529-
ECR3E-HA); primer 11/primer 12
pSecTag 2C
 N402- C449-ECR3E-HA
PCR amplification: Reaction 1 (template   pcDNA3 LTBP-1S); primer 29: 
cccaagcttggcctggtggaatgggttatacg; primer 30: cgggatcccggctgggagaggtggag
pSecTag 2C
 N19- C449-ECR3E-HA
PCR amplification: Reaction 1 (template   pcDNA3 LTBP-1S); primer 31: 
cccaagcttggagtaaccacactggccgcatc; primer 32: cgggatcccttggcaaaaggtgttgttaaccc
pcDNA3
LTBP-1S  403-449
PCR amplification: Reaction 1 (template   pcDNA3 LTBP-1S); primer 33: gcagctatcgatgtacctgc; primer 
34: gggatatcacagatttccttaaaagcagctgt; Reaction 2 (template   pcDNA3 LTBP-1S); primer 35: 
gggttaacaaggaagagccagtggaggc; primer 36: cccctgtccacaggtgcac
pcDNA3
LTBP-1S-HA
PCR amplification: Reaction 1 (template   respective pcDNA3 untagged); primer 37: 
cccaagcttgggttcatagacgcaggccaatc
pcDNA3
LTBP-1S  403-449-HA
primer 38: ctagtctagactaagcgtagtctgggacgtcgtatgggtactccaggtcactgtctttctc
pcDNA3; LTBP-1S  N402-HA
PMX
 N402- C449-ECR3E-HA
PCR amplification: Reaction 1 (template   respective pSecTag2C vectors); primer 39: 
ttagtagaattcatggagacagacacactcctgc
PMX
 N402- C449-ECR3E-HA; L1→L2
primer 40: ccgctcgagcggttatcaggcgtagtcgggcacgtc
PMX;  N449- C529-ECR3E-HA
pcDNA3
LTBP-3 with LTBP-1 hinge
PCR amplification: Reaction 1 (template   pcDNA3 LTBP-3); primer 41: gccaggatatcaacgaatgtgcgatgccc; 
primer 42: cccattccaccagggcagatctccttgaaggc; Reaction 2 (template   pcDNA3 LTBP-1); primer 43: 
caaggagatctgccctggtggaatgggttatacgg; primer 44: ttcaatcggcattcattgatttctgtcacttgagtagg; Reaction 4 
(template   pcDNA3 LTBP-3); primer 45: aaatcaatgaatgccgattgaaccagaatatctgtgg; primer 46: 
gcaggtgctagggtcgcgacactcLTBP-1 in integrin-mediated TGF-  activation | Annes et al. 733
ECM deposition of latent TGF-  was testing by using, CHO-K7, SW-
480, or 2T3 osteoblast precursor cells transduced with PMX virus, 402-
449ECR3E virus, or 450529ECR3E virus and subsequently transfected with
human TGF- 1 cDNA. 2 d after transfection, cells were replated in 96-
well plates, 20,000 cells per well. 24 h later, cells in 96-well plates were
washed once with PBS, and detached from the cell culture plate with 20
mM EDTA/PBS at 37 C for 30–40 min. Wells were washed two more times
with PBS, and 100  l DMEM was added into each well. The 96-well plate
was incubated at 80 C for 20 min to activate and release matrix-bound la-
tent TGF- . The media were collected and put onto TMLC to measure
TGF-  activity.
To test the ability of CHO-ECR3E-2HA/ 6 cells to activate latent TGF- 
deposited in the ECM, CHO cells stably transfected with ECR3E (CHO-
ECR3E) or LTBP-1S (CHO-LTBP) were allowed to synthesize a matrix in
96-wells (5.0   10
4 cells per well) for 48 h before they were removed with
PBS/15 mM EDTA. CHO-ECR3E-2HA/ 6 cells (2.0   10
4 cells per well) or
SW480-ECR3E-2HA/ 6 cells (2.5   10
4 cells per well) were plated on the
preformed matrices with reporter cells (1.5   10
4 cells per well; 100  l fi-
nal volume) to measure TGF-  activity. A TGF-  neutralizing antibody
(1D11; 15  g/ml) or an  V 6-blocking antibody (10D5; 20  g/ml) was
added to co-culture wells as appropriate.
To test if artificially targeting ECR3E-2HA–bound latent TGF-  to the vi-
cinity of the ECM restored latent TGF-  activation, the wells of a 96-well
plate were either coated with the mouse mAb HA.11 (25  g/ml) in PBS or
mock coated for 1.5 h at 37 C. The wells were washed with DMEM/10%
FCS, and various cell types (SW480/ 6, SW480-ECR3E-2HA/ 6, SW480-
ECR3E-2HA, SW480-PMX) were added (2.0   10
4 cells per well) to both
anti-HA–coated and mock-coated wells. TMLC (1.5   10
4 cells per well)
were added to each well to a final volume of 100  l per well. TGF-  neu-
tralizing antibody (1D11; 15  g/ml) was added as appropriate. After 16–
24 h, luciferase activity was assayed.
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